这是用户在 2025-1-10 4:32 为 https://pubmed.ncbi.nlm.nih.gov/38729160/ 保存的双语快照页面，由 沉浸式翻译 提供双语支持。了解如何保存？
Skip to main page content
U.S. flag

An official website of the United States government
美国政府的官方网站

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 10;42(6):946-967.
doi: 10.1016/j.ccell.2024.04.009. Epub 2024 May 9.
审查
Epub 2024 5 月 9 日。

Understanding the complexity of p53 in a new era of tumor suppression
了解肿瘤抑制新时代 p53 的复杂性

Yanqing Liu  1 , Zhenyi Su  1 , Omid Tavana  1 , Wei Gu  2
刘 燕青 1 ， 苏振义  1 ， Omid Tavana  1 ， 顾 伟 2
Affiliations   背景
Review

Understanding the complexity of p53 in a new era of tumor suppression
了解肿瘤抑制新时代 p53 的复杂性

Yanqing Liu et al. Cancer Cell. .

Abstract   抽象

p53 was discovered 45 years ago as an SV40 large T antigen binding protein, coded by the most frequently mutated TP53 gene in human cancers. As a transcription factor, p53 is tightly regulated by a rich network of post-translational modifications to execute its diverse functions in tumor suppression. Although early studies established p53-mediated cell-cycle arrest, apoptosis, and senescence as the classic barriers in cancer development, a growing number of new functions of p53 have been discovered and the scope of p53-mediated anti-tumor activity is largely expanded. Here, we review the complexity of different layers of p53 regulation, and the recent advance of the p53 pathway in metabolism, ferroptosis, immunity, and others that contribute to tumor suppression. We also discuss the challenge regarding how to activate p53 function specifically effective in inhibiting tumor growth without harming normal homeostasis for cancer therapy.
p53 于 45 年前被发现为一种 SV40 大 T 抗原结合蛋白，由人类癌症中最常突变的 TP53 基因编码。作为一种转录因子，p53 受到丰富的翻译后修饰网络的严格调控，以在肿瘤抑制中执行其多种功能。尽管早期研究确定 p53 介导的细胞周期停滞、凋亡和衰老是癌症发展的典型障碍，但已经发现了越来越多的 p53 新功能，并且 p53 介导的抗肿瘤活性的范围在很大程度上扩大了。在这里，我们回顾了 p53 调节不同层次的复杂性，以及 p53 通路在代谢、铁死亡、免疫和其他有助于肿瘤抑制的途径方面的最新进展。我们还讨论了如何激活 p53 功能的挑战，该功能特别有效地抑制肿瘤生长，而不会损害癌症治疗的正常稳态。

Keywords: MDM2; MDMX; apoptosis; cancer treatment; cell competition; cell-cycle arrest; ferroptosis; genome stability; immunity; metabolism; metastasis; p53; p53 mutation; p63; p73; senescence; stem cell dynamics; targeting p53; tumor suppression.
关键字： MDM2;MDMX 的;细胞凋亡;癌症治疗;细胞竞争;细胞周期停滞;铁死亡;基因组稳定性;免疫;新陈代谢;转移;第 53 页;p53 突变;第 63 页;第 73 页;衰老;干细胞动力学;靶向 p53;肿瘤抑制。

PubMed Disclaimer  PubMed 免责声明

Conflict of interest statement
利益冲突声明

Declaration of interests O.T. is currently an employee of AstraZeneca and has stock ownership in AstraZeneca.
利益声明 O.T. 目前是阿斯利康的员工，并拥有阿斯利康的股票。

Figures   数字

Figure 1.
Figure 1.. Timeline of research in the p53 field over the past 45 years.
This figure shows the number of publications recorded in PubMed every five years since 1979, along with key discoveries about p53. Due to space constraints, many excellent studies cannot be included here. LFS, Li-Fraumeni syndrome; PTM, post-translational modification; GOF, gain-of-function; NDD, neurodegenerative disease; iPSC, induced pluripotent stem cell; TAD2, transactivation domain 2; KR, lysine-to-arginine mutation.
Figure 2.
Figure 2.. Regulation of p53.
The expression and activity of p53 are controlled by multilayered regulation at the DNA, RNA, and protein levels. At the DNA level, SNPs (e.g. P72R) and mutations (e.g. R273H) may occur in the p53 gene. p53 possesses two promoters, which can be methylated and silenced. The transcription of p53 gene is activated or suppressed by various TFs (e.g. HOXA5). At the RNA level, the cellular localization, stability, and translation of p53 mRNA are modulated by RNA-binding proteins (e.g. TIA1) and ncRNAs (e.g. miR-380–5p). p53 pre-mRNA and mRNA can undergo alternative splicing and alternative translation, respectively. At the protein level, p53 folding, stability, cellular localization, DNA binding, transactivation ability, and target selection are primarily mediated by post-translational modifications (e.g. ubiquitination, phosphorylation, and acetylation) and cofactors (e.g. MDM2, MDMX, and CBP). Diverse stress signals (e.g. DNA damage) can activate p53, and its activity as a TF is highly dynamic. p53 also exhibits TF-independent function in cytoplasm (e.g. promoting apoptosis via interacting with Bcl-XL). P1 and P2, promoter 1 and 2; SNP, single nucleotide polymorphism; E3, E3 ubiquitin ligase; TF, transcription factor; Me, methylation; Ub, ubiquitination; P, phosphorylation; Ac, acetylation.
Figure 3.
Figure 3.. Functions and physiopathological roles of p53.
p53 exhibits diverse and complex functions: classical functions (including inducing cell-cycle arrest, apoptosis, and senescence, and maintaining genome stability) and other functions (such as mediating metabolism, ferroptosis, stem cell dynamics, cell competition, metastasis, and immunity). Due to its wide array of functions, p53 plays a crucial role in numerous physiological processes (e.g., reproduction, development, regeneration, repair, and aging) and pathological disorders (like neurodegenerative disease, radiation sickness, chemotherapeutic toxicity, ischemic injury, metabolic disease, and cancer). The black curves illustrate how specific functions of p53 contribute to its role in linked physiological or pathological processes.
Figure 4.
Figure 4.. p53 and cancer hallmarks.
Activity of WT p53 antagonizes all the hallmarks of cancer, as depicted in the surrounding ovals. In contrast, alterations in p53, including repression, mutation, and deletion, promote these hallmarks. It is partially adapted from reference.
Figure 5.
Figure 5.. Targeting p53 in cancer.
Various methods have been developed to target p53 for tumor treatment. In tumors retaining WT p53, RG7388, APG-115, KRT-232, and ALRN-6924 are used to disrupt the PPIs between p53 and MDM2 or MDMX, while RITA, tenovin-6, ML364, and UNC0379 target other negative regulators of p53. Activation of p53 can be utilized in cyclotherapy to protect normal cells, or in combination with other treatments for synergistic tumor eradication. WT p53 can be misfolded into a pseudo-mutant conformation, which may be reversed with appropriate drugs. Downstream targets of p53 are also potential therapeutic targets to partially reactivate the p53 signaling pathway. In tumors containing p53 missense mutations, APR-246, COTI-2, ATO, and PAT are capable of restoring the WT conformation of many p53 mutants. Specific agents such as PhiKan083, PK7088, PC14586, KG13, and MS78 target the p53 Y220C mutation, while ZMC1 is used for the p53 R175H mutant. Additionally, genome editing may be useful in correcting p53 gene mutations. NSC59984, ganetespib, MCB-613, and nanoreceptors are able to degrade mutant p53. ONYX-015, an oncolytic virus, specifically kills tumor cells with p53 mutations. Agents like ReACp53 and ADH-6 resolve the aggregation of mutant p53, partially restoring WT p53 functions. Antibodies like P1C1TM and H2-scDb, which recognize neoantigens derived from mutant p53, mediate tumor cell elimination by immune cells. p53MVA and p53-SLP are p53 vaccines used in immunotherapy. Mutant p53 neoantigens are also useful for developing adoptive cell therapies. Mutant p53 DNA fragments and proteins (including their aggregates) can be utilized for tumor diagnosis and prognosis. In tumors with p53 nonsense mutations, G418, 2,6-DAP, CC-90009, and NMDI14 can induce the readthrough of p53 mutant mRNAs, or inhibiting NMD. In p53-null tumors, delivery of p53 protein, mRNA, and DNA may restore p53 expression and eliminate tumor cells. LOF, loss-of-function; DNE, dominant-negative effect; GOF, gain-of-function; NR, negative regulator of p53.
See this image and copyright information in PMC

Similar articles   相关文章

See all similar articles   查看所有相似文章

Cited by   施引文献

See all "Cited by" articles
查看所有 “Cited by” 文章

References   引用

    1. Dolgin E (2017). The most popular genes in the human genome. Nature 551, 427–431. - PubMed
      多尔金 E（2017 年）。人类基因组中最受欢迎的基因。自然 551， 427–431。 - 公共医学
    1. Levine AJ & Oren M (2009). The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9, 749–758. - PMC - PubMed
      莱文AJ和奥伦M（2009）。p53 的前 30 年：变得越来越复杂。Nat Rev 癌症 9， 749–758。 - PMC 公司 - 公共医学
    1. Hainaut P & Wiman KG (2009). 30 years and a long way into p53 research. Lancet Oncol 10, 913–919. - PubMed
      Hainaut P & Wiman KG （2009）。30 年，进入 p53 研究的漫长道路。柳叶刀 Oncol 10， 913-919。 - 公共医学
    1. Soussi T (2010). The history of p53. A perfect example of the drawbacks of scientific paradigms. EMBO Rep 11, 822–826. - PMC - PubMed
      苏西 T （2010）。p53 的历史。科学范式缺点的完美例子。EMBO 代表 11， 822–826。 - PMC 公司 - 公共医学
    1. Barnoud T, Indeglia A & Murphy ME (2021). Shifting the paradigms for tumor suppression: lessons from the p53 field. Oncogene 40, 4281–4290. - PMC - PubMed
      Barnoud T， Indeglia A & Murphy ME （2021）。改变肿瘤抑制的范式：来自 p53 领域的经验教训。癌基因 40， 4281–4290。 - PMC 公司 - 公共医学

Substances